Regrets For Valeant's Ackman, Pearson; Big Pay For Papa
Outgoing Valeant Pharmaceuticals International Inc.'s CEO Michael Pearson and board member Bill Ackman expressed regret during an April 27 Senate hearing about the price hikes of some of the Canadian firm's drugs and pledged change at the embattled company. Meanwhile, the company in a late-day securities filing disclosed it planned to pay incoming CEO Joseph Papa more than $67m in cash, restricted stock and options, which shocked and angered the Senate committee leaders.
You may also be interested in...
Valeant's prospects were dim with or without Pershing Square's continued backing, but at least one analyst says Ackman's departure sends a signal that business won't rebound at the Canadian specialty pharma any time soon.
Mylan's $600 price tag for its emergency anaphylaxis treatment EpiPen (epinephrine) could spur more than probes into the company's pricing practices. It could turn into a wider investigation into industry's use of patient assistance programs.
The things that keep Sean Harper up at night have changed over the last few years as science has advanced and the drug development landscape has changed. Harper, who is the head of R&D at big biotech Amgen Inc., once worried that his company wouldn't be able to keep up, now he's concerned with where the money is going to come from.